• Organizations: Kiora Pharmaceuticals
Kiora's KIO-104 receives US patent for expanded protection of inflammatory retinal diseases
Pipeline

Kiora's KIO-104 receives US patent for expanded protection of inflammatory retinal diseases

The investigational small molecule’s intellectual property and potential market exclusivity are now protected through 2043.
Kiora Pharma secures IRD grant for late-stage RP trial
Pipeline

Kiora Pharma secures IRD grant for late-stage RP trial

Funding from the Choroideremia Research Foundation will support testing validation in the ABACUS-2 phase 2 trial on KIO-301, a molecular photoswitch.
Théa acquires exclusive rights to Kiora's IRD therapy
Pipeline

Théa acquires exclusive rights to Kiora's IRD therapy

Commercialization agreement involves clinical development of KIO-301 for retinitis pigmentosa.
Kiora granted US patents covering local ocular delivery for KIO-100 compounds
Pipeline

Kiora granted US patents covering local ocular delivery for KIO-100 compounds

Intellectual property provides protection and market exclusivity for the small molecules and therapeutic applications like posterior non-infectious uveitis.
Kiora shifts clinical focus to rare retinal diseases
Pipeline

Kiora shifts clinical focus to rare retinal diseases

Company is also seeking potential strategic partnerships to advance its anterior segment program.
FDA approves Kiora to start phase 2 study of KIO-101
Pipeline

FDA approves Kiora to start phase 2 study of KIO-101

Upcoming study will assess treatment for ocular presentation of rheumatoid arthritis and other autoimmune diseases.
First patient dosed in phase 1b study for retinitis pigmentosa
Pipeline

First patient dosed in phase 1b study for retinitis pigmentosa

Kiora Pharmaceuticals announced the dosing of its first patient in a first-in-human-label clinical trial for the candidate KIO-301, designed to restore vision loss in patients with retinitis pigmentosa (RP)